300831-22-5

Basic information

• Product Name: 2-Oxazolidinone, 3-(1-oxo-8-nonenyl)-4-(phenylmethyl)-, (4S)-
• CAS NO: 300831-22-5
• Molecular Formula: C19H25NO3
• Molecular Weight: 315.412
• Mol File: 300831-22-5.mol

Chemical Properties

• CAS DataBase Reference: 2-Oxazolidinone, 3-(1-oxo-8-nonenyl)-4-(phenylmethyl)-, (4S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxazolidinone, 3-(1-oxo-8-nonenyl)-4-(phenylmethyl)-, (4S)-(300831-22-5)
• EPA Substance Registry System: 2-Oxazolidinone, 3-(1-oxo-8-nonenyl)-4-(phenylmethyl)-, (4S)-(300831-22-5)

Safety Data

• Hazardous Substances Data: 300831-22-5(Hazardous Substances Data)

Upstream product

• 31642-67-8 non-8-enoic acid 
• 101711-90-4 (S)-4-benzyl-2-oxazolidinone lithium salt 
• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 
• 2695-48-9 8-Bromo-1-octene 

Downstream Products

• 300831-21-4 (S)-2-(tert-butoxycarbonylamino)non-8-enoic acid 
• 770742-83-1 (2R,5S,14S,16aS)-5-tert-Butoxycarbonylamino-2-(7-methoxy-2-phenyl-quinolin-4-yloxy)-4,16-dioxo-hexadecahydro-3a,15-diaza-cyclopentacyclopentadecene-14-carboxylic acid methyl ester 
• 770742-80-8 (2R,5S,14R,16aS)-5-tert-Butoxycarbonylamino-2-(7-methoxy-2-phenyl-quinolin-4-yloxy)-4,16-dioxo-hexadecahydro-3a,15-diaza-cyclopentacyclopentadecene-14-carboxylic acid methyl ester 
• 770742-65-9 (S)-2-{[(2S,4R)-1-((S)-2-tert-Butoxycarbonylamino-non-8-enoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-pent-4-enoic acid methyl ester 
• 770742-64-8 (R)-2-{[(2S,4R)-1-((S)-2-tert-Butoxycarbonylamino-non-8-enoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-pent-4-enoic acid methyl ester 
• 770742-79-5 (Z)-(2R,5S,14R,16aS)-5-tert-Butoxycarbonylamino-2-(7-methoxy-2-phenyl-quinolin-4-yloxy)-4,16-dioxo-2,3,4,5,6,7,8,9,10,13,14,15,16,16a-tetradecahydro-1H-3a,15-diaza-cyclopentacyclopentadecene-14-carboxylic acid methyl ester 
• 300831-24-7 [(S)-1-((S)-4-Benzyl-2-oxo-oxazolidine-3-carbonyl)-oct-7-enyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION

The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables R1-R9, R16, R18, R19, n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.

Potent inhibitors of the hepatitis C virus NS3 protease: Design and synthesis of macrocyclic substrate-based β-strand mimics

The virally encoded NS3 protease is essential to the life cycle of the hepatitis C virus (HCV), an important human pathogen causing chronic hepatitis, cirrhosis of the liver, and hepatocellular carcinoma. The design and synthesis of 15-membered ring β-strand mimics which are capable of inhibiting the interactions between the HCV NS3 protease enzyme and its polyprotein substrate will be described. The binding interactions between a macrocyclic ligand and the enzyme were explored by NMR and molecular dynamics, and a model of the ligand/enzyme complex was developed.